医用大麻使用模式及对阿片类药物和其他处方药、酒精、烟草及非法物质的替代情况；一项针对授权患者的横断面调查结果。
Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients.
机构信息
Social Dimensions of Health, University of Victoria, 3800 Finnerty Rd., Victoria, BC, V8P 5C2, Canada.
, Tilray, 1100 Maughan Rd, Nanaimo, BC, V9X1J2, Canada.
出版信息
Harm Reduct J. 2019 Jan 28;16(1):9. doi: 10.1186/s12954-019-0278-6.
BACKGROUND
A 239-question cross-sectional survey was sent out via email in January 2017 to gather comprehensive information on cannabis use from Canadian medical cannabis patients registered with a federally authorized licensed cannabis producer, resulting in 2032 complete surveys.
METHODS
The survey gathered detailed demographic data and comprehensive information on patient patterns of medical cannabis use, including questions assessing the self-reported impact of cannabis on the use of prescription drugs, illicit substances, alcohol, and tobacco.
RESULTS
Participants were 62.6% male (n = 1271) and 91% Caucasian (n = 1839). The mean age was 40 years old, and pain and mental health conditions accounted for 83.7% of all respondents (n = 1700). Then, 74.6% of respondents reported daily cannabis use (n = 1515) and mean amount used per day was 1.5 g. The most commonly cited substitution was for prescription drugs (69.1%, n = 953), followed by alcohol (44.5%, n = 515), tobacco (31.1%, n = 406), and illicit substances (26.6%, n = 136). Opioid medications accounted for 35.3% of all prescription drug substitution (n = 610), followed by antidepressants (21.5%, n = 371). Of the 610 mentions of specific opioid medications, patients report total cessation of use of 59.3% (n = 362).
CONCLUSIONS
This study offers a unique perspective by focusing on the use of a standardized, government-regulated source of medical cannabis by patients registered in Canada's federal medical cannabis program. The findings provide a granular view of patient patterns of medical cannabis use, and the subsequent self-reported impacts on the use of opioids, alcohol, and other substances, adding to a growing body of academic research suggesting that increased regulated access to medical and recreational cannabis can result in a reduction in the use of and subsequent harms associated with opioids, alcohol, tobacco, and other substances.
背景
2017 年 1 月，通过电子邮件向加拿大医用大麻患者发送了一份 239 个问题的横断面调查，以从联邦授权的持牌大麻生产商处收集关于大麻使用的综合信息，共收到 2032 份完整的调查。
方法
该调查收集了详细的人口统计数据和患者医用大麻使用模式的综合信息，包括评估大麻对处方药、非法药物、酒精和烟草使用的自我报告影响的问题。
结果
参与者中 62.6%为男性（n=1271），91%为白种人（n=1839）。平均年龄为 40 岁，83.7%的受访者（n=1700）患有疼痛和心理健康疾病。然后，74.6%的受访者报告每天使用大麻（n=1515），平均每天使用量为 1.5 克。最常被引用的替代物是处方药（69.1%，n=953），其次是酒精（44.5%，n=515）、烟草（31.1%，n=406）和非法药物（26.6%，n=136）。阿片类药物占所有处方药替代物的 35.3%（n=610），其次是抗抑郁药（21.5%，n=371）。在 610 种特定阿片类药物的提及中，患者报告完全停止使用的占 59.3%（n=362）。
结论
本研究通过关注在加拿大联邦医用大麻计划中注册的患者使用标准化、政府监管的医用大麻来源，提供了一个独特的视角。研究结果提供了患者医用大麻使用模式的详细视图，以及随后对阿片类药物、酒精和其他物质使用的自我报告影响，这增加了越来越多的学术研究表明，增加对医用和娱乐用大麻的监管准入可以减少阿片类药物、酒精、烟草和其他物质的使用以及与之相关的危害。
Zotero 插件